Lyn Inhibitors
2 drugsAbout Lyn
Lyn is a member of the Src family of tyrosine kinases involved in cell growth, differentiation, and immune responses. As a signaling protein, its dysregulation is implicated in various diseases.
Lyn is a therapeutic target with two FDA-approved drugs, BOSULIF and OFEV, despite the lack of direct genetic evidence linking it to specific diseases. These drugs are used in respiratory diseases and other conditions, highlighting the potential for clinical benefit by modulating Lyn activity.
Lyn is targeted by two FDA-approved small molecule drugs: OFEV (Boehringer Ingelheim) and BOSULIF (PF PRISM CV). These drugs are approved for respiratory diseases and other conditions.
Top Lyn Drugs
The competitive landscape consists of two companies, PF PRISM CV and Boehringer Ingelheim, with approved drugs targeting Lyn.
The limited number of players suggests a relatively uncongested market, potentially easing entry for new competitors.
Lyn Drug Modality Landscape
Modalities
Routes of Administration
Lyn is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
Lyn Clinical Trials 115 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Lyn. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 47 | 37 | 6 | 4 | 86% |
| Phase 2 | 36 | 21 | 11 | 4 | 66% |
| Phase 3 | 22 | 14 | 2 | 6 | 88% |
| Phase 4 | 10 | 6 | 2 | 2 | 75% |
Top Sponsors
By Modality
Top Conditions
Lyn Drug Approval Timeline (2012 - 2014)
The first drug targeting Lyn was approved in 2012 (BOSULIF), with the most recent approval in 2014 (OFEV), spanning a 3-year period.
The limited approval timeline suggests a potentially saturated market or challenges in developing new Lyn-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 57 (17 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Lyn. A trial counts if an approved drug acting on Lyn is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.